Stockscreener 앱 받기
1.045
1.42%
-0.015
시간 외 거래:
1.04
-0.005
-0.48%
전일 마감가:
$1.06
열려 있는:
$1.05
하루 거래량:
9,042
Relative Volume:
0.08
시가총액:
$10.60M
수익:
-
순이익/손실:
$-15.42M
주가수익비율:
-0.5938
EPS:
-1.76
순현금흐름:
$-13.41M
1주 성능:
-7.11%
1개월 성능:
-28.91%
6개월 성능:
-55.53%
1년 성능:
-50.00%
1일 변동 폭
$1.02
$1.06
1주일 범위
$1.02
$1.20
52주 변동 폭
$1.02
$3.10
Indaptus Therapeutics Inc Stock (INDP) Company Profile
명칭
Indaptus Therapeutics Inc
전화
(646) 427-2727
주소
3 COLUMBUS CIRCLE, NEW YORK
INDP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| INDP | 1.045 | 10.60M | 0 | -15.42M | -13.41M | -1.76 |
| VRTX | 450.37 | 115.10B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.74 | 35.07B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.20B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.23 | 25.09B | 3.30B | -501.07M | 1.03B | 11.54 |
Indaptus Therapeutics Inc 주식(INDP)의 최신 뉴스
Maxim Group Has Lowered Expectations for Indaptus Therapeutics (NASDAQ:INDP) Stock Price - Defense World
Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Indaptus Therapeutics Inc (INDP) Quarterly 10-Q Report - Quartzy
Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology - The Manila Times
Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting - The Manila Times
Indaptus' Decoy20 Shows Promise: Phase 1 Trial Reports Safe Weekly Dosing in Cancer Study | INDP Stock News - StockTitan
Indaptus Therapeutics to Present at Two Upcoming Investor Conferences - The Manila Times
Indaptus Therapeutics partners with BeiGene for cancer study By Investing.com - Investing.com Canada
Indaptus Therapeutics Shares Rise After Pact to Develop Cancer Treatment - Morningstar
Indaptus Therapeutics partners with BeiGene for cancer study - Investing.com
Indaptus Therapeutics Announces Clinical Supply Agreement - GlobeNewswire
Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations - The Manila Times
Indaptus Therapeutics, Inc. Enters into Clinical Supply Agreement with Beigene Switzerland GmbH - Marketscreener.com
Provident Bank's First-Time Home Buyer Survey Reveals That While Homeownership Continues to Be Challenging, Many Americans Are Finding Their Home in Less Than a Year - The Manila Times
Indaptus Therapeutics Initiates Unrestricted Enrollment of - GlobeNewswire
Indaptus Therapeutics (INDP) Price Target Increased by 25.00% to 10.20 - MSN
Indaptus Therapeutics Founder and Chief Scientific Officer - GlobeNewswire
Indaptus Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit - The Manila Times
Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Increases By 140.5% - Defense World
Cybin (NYSEAMERICAN:CYBN) Shares Down 4.4% - Defense World
Japan Tobacco Inc. (OTCMKTS:JAPAY) Short Interest Update - Defense World
Sei Investments Co. Has $17.72 Million Position in Teradata Co. (NYSE:TDC) - Defense World
Indaptus Therapeutics (NASDAQ:INDP) Stock Price Down 9.2% - Defense World
Intelligent Bio Solutions Inc. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results and Operational Highlights - Marketscreener.com
Kaskela Law LLC Announces Shareholder Investigation of Integra LifeSciences Holdings Corp. (NASDAQ: IART) and Encourages Long-Term IART Shareholders to Contact the Firm - Business Wire
The Escalator: Imre, Kyverna Therapeutics, The Bloc and more - MM+M Online
StockNews.com Downgrades Independent Bank (NASDAQ:INDB) to Sell - Defense World
Integrated BioPharma (OTCMKTS:INBP) Trading Down 2.2% - Defense World
Indivior PLC REMINDER – INDV Stockholders Should Contact - GlobeNewswire
IBTX stock hits 52-week high at $60.77 amid robust growth - Investing.com
INDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud Lawsuit - PR Newswire
Northland Capmk Equities Analysts Cut Earnings Estimates for Indivior PLC (NASDAQ:INDV) - MarketBeat
Holdings of Intelligent Bio Solutions Inc (INBS) are aligned with the stars - SETE News
Upward Trajectory: Intelligent Bio Solutions Inc (INBS) Posts a Gaine, Closing at 2.48 - The Dwinnex
Imunon (NASDAQ:IMNN) Shares Up 5.6% - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Indivior PLC of Class Action Lawsuit and Upcoming DeadlinesINDV - PR Newswire
Financial Health Check: Examining Indivior Plc (INDV)’s Key Ratios - The Dwinnex
Class Action Lawsuit Against Indivior PLC (NASDAQ:INDV) - TipRanks
Ready to Jump After Recent Trade: Indivior Plc (INDV) - SETE News
Indivior PLC Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsINDV - PR Newswire
Intelligent Bio Solutions Inc’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle
DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value - GlobeNewswire
Technical analysis of Intelligent Bio Solutions Inc (INBS) stock chart patterns - US Post News
Negative FDA AdCom vote on Ocaliva - The Pharma Letter
The Gross Law Firm Reminds Indivior Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 1, 2024INDV - PR Newswire
Piper Sandler Reaffirms “Overweight” Rating for Indivior (NASDAQ:INDV) - Defense World
INDV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Indivior PLC Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Indivior PLC (NASDAQ:INDV) Shares Sold by Royal London Asset Management Ltd. - MarketBeat
INVESTOR ALERT: DiCello Levitt LLP Shareholder Class Action - GlobeNewswire
Indivior's (INDV) Overweight Rating Reiterated at Piper Sandler - MarketBeat
Intl Paper Co stock hits 52-week high at $49.25 amid market rally By Investing.com - Investing.com South Africa
Indaptus Therapeutics Inc (INDP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
3.56%
자본화:
|
볼륨(24시간):